GGrantIndex
Sort

39,280 grants matching leukemia

NCTN Deep South Research Consortium

$450,954
Charles A. Leath · University Of Alabama At Birmingham · UG1 · FY2025 · CA

Overcoming ibrutinib resistance in mantle cell lymphoma

$450,951
Alexey V. Danilov · Beckman Research Institute/City Of Hope · R01 · FY2022 · CA

The role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AML

$450,915
Jianjun Chen · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA

Discovery and targeting of apoptosis resistance mechanisms in high-risk T-ALL

$450,867
Alejandro Gutierrez · Boston Children'S Hospital · R01 · FY2015 · CA

Impact of Leukemia Microenvironment on Response to Targeted Therapies in AML

$450,830
Anupriya Agarwal · Oregon Health & Science University · U54 · FY2019 · CA

Role of IL-17 receptor A in aging bone remodeling

$450,806
Hicham M Drissi · Emory University · R01 · FY2025 · AG

Targeting microRNAs to eradicate leukemia stem cells

$450,769
Ya-Huei Kuo · Beckman Research Institute/City Of Hope · R01 · FY2018 · CA

The role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AML

$450,740
Jianjun Chen · Beckman Research Institute/City Of Hope · R01 · FY2022 · CA

Leukemia Specific Splice Isoforms as Neo-Antigens for T-Cell Immunotherapy

$450,736
Paul Michael Armistead · Univ Of North Carolina Chapel Hill · R01 · FY2020 · CA

An innovative integrated computational framework using gene signatures for patient stratification

$450,696
Chao Cheng · Baylor College Of Medicine · R01 · FY2025 · CA

Understanding Richter's Transformation in the targeted therapies era

$450,684
Rosa Lapalombella · Ohio State University · R01 · FY2024 · CA

Regulation of MLK3 by LATS

$450,666
Deborah N Chadee · University Of Toledo · R15 · FY2019 · CA

Chemical manipulation of creatine kinases to treat acute myeloid leukemia

$450,655
Edward Thomas Chouchani · Dana-Farber Cancer Inst · R21 · FY2021 · CA

ETS1-dependent combinatorial control of oncogenic transcription in Notch-activated T-ALL

$450,646
Mark Y Chiang · University Of Michigan At Ann Arbor · R01 · FY2024 · CA

Improved Targeting Strategies

$450,632
Oliver W. Press · Fred Hutchinson Cancer Research Center · P01 · FY2009 · CA

Diet and Alcohol Induced Epigenetic Changes in Oral Cavity Carcinogenesis Model

$450,588
Lorraine J Gudas · Weill Medical Coll Of Cornell Univ · R01 · FY2012 · AA

Aberrant megakaryopoiesis in the myeloproliferative neoplasms.

$450,538
John D Crispino · Northwestern University At Chicago · R01 · FY2019 · HL

Cancer and Leukemia Group B - The Ohio State University

$450,518
Clara D Bloomfield · Ohio State University · U10 · FY2008 · CA

Clinical Trials Shared Resource

$450,517
Jordan D Berlin · Vanderbilt University · P30 · FY2014 · CA

Mechanisms of targeting cellular self-renewal in glioblastoma

$450,510
Hatem Sabaawy · Rbhs -Cancer Institute Of New Jersey · R01 · FY2019 · CA

Single cell growth assay for residual cells in acute lymphoblastic leukemia

$450,496
Scott R Manalis · Massachusetts Institute Of Technology · R33 · FY2017 · CA

Defining and targeting asparaginase resistance mechanisms in high-risk acute leukemias

$450,484
Alejandro Gutierrez · Boston Children'S Hospital · R01 · FY2021 · CA

Development of Chimeric Antigen Receptors Targeting Multiple Myeloma

$450,431
James Kochenderfer · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA

Targeting the Notch:Myc axis in leukemia/lymphoma

$450,421
Warren S Pear · University Of Pennsylvania · R01 · FY2019 · CA

Overcoming ibrutinib resistance in mantle cell lymphoma

$450,309
Alexey V. Danilov · Beckman Research Institute/City Of Hope · R01 · FY2025 · CA